121 related articles for article (PubMed ID: 10531630)
1. Three oral formulations of methadone. A clinical and pharmacodynamic comparison.
Gourevitch MN; Hartel D; Tenore P; Freeman K; Marion I; Hecht J; Lowinson J
J Subst Abuse Treat; 1999 Oct; 17(3):237-41. PubMed ID: 10531630
[TBL] [Abstract][Full Text] [Related]
2. Steady-state pharmacokinetics and pharmacodynamics in methadone maintenance patients: comparison of those who do and do not experience withdrawal and concentration-effect relationships.
Dyer KR; Foster DJ; White JM; Somogyi AA; Menelaou A; Bochner F
Clin Pharmacol Ther; 1999 Jun; 65(6):685-94. PubMed ID: 10391674
[TBL] [Abstract][Full Text] [Related]
3. Effect of saquinavir/ritonavir (1000/100 mg bid) on the pharmacokinetics of methadone in opiate-dependent HIV-negative patients on stable methadone maintenance therapy.
Jamois C; Smith P; Morrison R; Riek M; Patel A; Schmitt C; Morcos PN; Zhang X
Addict Biol; 2009 Jul; 14(3):321-7. PubMed ID: 19523046
[TBL] [Abstract][Full Text] [Related]
4. A double-blind, randomized, parallel group study to compare the efficacy, safety and tolerability of slow-release oral morphine versus methadone in opioid-dependent in-patients willing to undergo detoxification.
Madlung-Kratzer E; Spitzer B; Brosch R; Dunkel D; Haring C
Addiction; 2009 Sep; 104(9):1549-57. PubMed ID: 19686525
[TBL] [Abstract][Full Text] [Related]
5. Change intolerance to shifts in methadone formulation: a preliminary investigation.
Silver JS; Shaffer HJ
J Subst Abuse Treat; 1996; 13(4):331-9. PubMed ID: 9076651
[TBL] [Abstract][Full Text] [Related]
6. Subjective and physiological responses among racemic-methadone maintenance patients in relation to relative (S)- vs. (R)-methadone exposure.
Mitchell TB; Dyer KR; Newcombe D; Salter A; Somogyi AA; Bochner F; White JM
Br J Clin Pharmacol; 2004 Dec; 58(6):609-17. PubMed ID: 15563359
[TBL] [Abstract][Full Text] [Related]
7. Subjective and objective symptoms in relation to plasma methadone concentration in methadone patients.
Hiltunen AJ; Lafolie P; Martel J; Ottosson EC; Boreus LO; Beck O; Borg S; Hjemdahl P
Psychopharmacology (Berl); 1995 Mar; 118(2):122-6. PubMed ID: 7617797
[TBL] [Abstract][Full Text] [Related]
8. Craving despite extremely high methadone dosage.
de Vos JW; Ufkes JG; van Brussel GH; van den Brink W
Drug Alcohol Depend; 1996 Mar; 40(3):181-4. PubMed ID: 8861396
[TBL] [Abstract][Full Text] [Related]
9. Within- and between- subject variability in methadone pharmacokinetics and pharmacodynamics in methadone maintenance subjects.
Hanna J; Foster DJ; Salter A; Somogyi AA; White JM; Bochner F
Br J Clin Pharmacol; 2005 Oct; 60(4):404-13. PubMed ID: 16187972
[TBL] [Abstract][Full Text] [Related]
10. The effect of quinidine, used as a probe for the involvement of P-glycoprotein, on the intestinal absorption and pharmacodynamics of methadone.
Kharasch ED; Hoffer C; Whittington D
Br J Clin Pharmacol; 2004 May; 57(5):600-10. PubMed ID: 15089813
[TBL] [Abstract][Full Text] [Related]
11. Major depressive disorder and patient satisfaction in relation to methadone pharmacokinetics and pharmacodynamics in stabilized methadone maintenance patients.
Elkader AK; Brands B; Dunn E; Selby P; Sproule BA
J Clin Psychopharmacol; 2009 Feb; 29(1):77-81. PubMed ID: 19142113
[TBL] [Abstract][Full Text] [Related]
12. [Methadone treatment and its dangers].
Reingardiene D; Jodziūniene L; Lazauskas R
Medicina (Kaunas); 2009; 45(5):419-25. PubMed ID: 19535889
[TBL] [Abstract][Full Text] [Related]
13. Utilization of plasma and urine methadone concentration measurements to limit narcotics use in methadone maintenance patients: II. Generation of plasma concentration response curves.
Kell MJ
J Addict Dis; 1995; 14(1):85-108. PubMed ID: 7632750
[TBL] [Abstract][Full Text] [Related]
14. Correlation between high methadone doses and methadone serum levels in methadone maintenance treatment (MMT) patients.
Adelson M; Peles E; Bodner G; Kreek MJ
J Addict Dis; 2007; 26(1):15-26. PubMed ID: 17439864
[TBL] [Abstract][Full Text] [Related]
15. Effects of pegylated interferon alfa-2b on the pharmacokinetic and pharmacodynamic properties of methadone: a prospective, nonrandomized, crossover study in patients coinfected with hepatitis C and HIV receiving methadone maintenance treatment.
Berk SI; Litwin AH; Arnsten JH; Du E; Soloway I; Gourevitch MN
Clin Ther; 2007 Jan; 29(1):131-8. PubMed ID: 17379053
[TBL] [Abstract][Full Text] [Related]
16. [Problems with maintenance therapy in opiate dependence and the clinical importance of methadone].
Wilczek H
Cas Lek Cesk; 1998 Nov; 137(23):725-8. PubMed ID: 9990177
[TBL] [Abstract][Full Text] [Related]
17. Use of 'very low-dose phenobarbital' to investigate compliance in patients on reducing doses of methadone (detoxification).
Wolff K; Hay AA; Raistrick D; Feely M
J Subst Abuse Treat; 1993; 10(5):453-8. PubMed ID: 8246320
[TBL] [Abstract][Full Text] [Related]
18. Buprenorphine versus methadone in the treatment of opioid dependence: self-reports, urinalysis, and addiction severity index.
Strain EC; Stitzer ML; Liebson IA; Bigelow GE
J Clin Psychopharmacol; 1996 Feb; 16(1):58-67. PubMed ID: 8834420
[TBL] [Abstract][Full Text] [Related]
19. Patterns of symptom complaints in methadone maintenance patients.
Dyer KR; White JM
Addiction; 1997 Nov; 92(11):1445-55. PubMed ID: 9519488
[TBL] [Abstract][Full Text] [Related]
20. Methadone maintenance treatment: the need to distinguish between holding dose, dose adequacy, satisfaction with methadone as a medication, and satisfaction with treatment.
Trujols J; Siñol N; de los Cobos JP
J Clin Psychopharmacol; 2010 Feb; 30(1):95-6; author reply 96. PubMed ID: 20075667
[No Abstract] [Full Text] [Related]
[Next] [New Search]
